Compugen Ltd (CGEN) Stock Price, Quote & News

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 765 8585

Fax: 972 3 765 8555

Website: cgen.com

Address:

Azrieli Center, Building D 26 Harokmim Street, Holon, Israel

Estimize May. 13 at 10:00 AM

Wall St is expecting -0.07 EPS for $CGEN Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/cgen?chart=historical&metric_name=eps&utm_c

0 · Reply

TwitteringTom May. 12 at 1:59 PM

$CGEN whast this dumo

0 · Reply

KoalaFlipper May. 9 at 3:19 PM

$CGEN can we stay at 3,00$ per share?

0 · Reply

TwitteringTom May. 8 at 2:14 PM

$CGEN what we thinking? anything of note coming out on earnings?

0 · Reply

KoalaFlipper May. 8 at 10:03 AM

$CGEN Earnings Forecast: For the next quarter (reporting ~May 18, 2026), a small loss per share (-$0.07) is estimated, with revenue anticipated around $1.57M–$2.14M.

0 · Reply

Estimize May. 7 at 12:03 PM

Wall St is expecting -0.07 EPS for $CGEN Q1 [Reporting 05/18 BMO] http://www.estimize.com/intro/cgen?chart=historical&metric_name=eps&utm_c

0 · Reply

KoalaFlipper May. 4 at 9:30 PM

$CGEN buy the dips :)

0 · Reply

AGC_Trader May. 1 at 1:45 PM

$CGEN did anyone else see the spike to $3.17 in PM?

0 · Reply

KoalaFlipper May. 1 at 1:16 PM

$CGEN todays price prob gonna be 2,80+

0 · Reply

Sobo90 May. 1 at 9:04 AM

$CGEN didnt insiders just sell? Maybe nothing or they dont expect good news for some time.

1 · Reply

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 4, 2026, 7:00 AM EDT - 9 days ago

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Apr 13, 2026, 8:45 AM EDT - 4 weeks ago

Compugen Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 4 weeks ago

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

2026-04-07T11:44:13.000Z - 5 weeks ago

Compugen initiated with a Buy at Lake Street

AZN GILD MRK

Mar 9, 2026, 8:40 AM EDT - 2 months ago

Compugen Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:30 AM EST - 2 months ago

Compugen Earnings Call Transcript: Q4 2025

2026-03-02T12:22:05.000Z - 2 months ago

Compugen reports Q4 EPS 60c vs. (7c) last year

Mar 2, 2026, 7:00 AM EST - 2 months ago

Compugen Reports Fourth Quarter and Full Year 2025 Results

Feb 26, 2026, 2:00 PM EST - 2 months ago

Compugen Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 7:00 AM EST - 2 months ago

Compugen to Participate in Upcoming Investor Conferences

Feb 17, 2026, 7:00 AM EST - 3 months ago

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Feb 12, 2026, 7:00 AM EST - 3 months ago

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

2026-01-07T11:10:47.000Z - 4 months ago

Compugen initiated with a Buy at H.C. Wainwright

2025-12-17T12:12:00.000Z - 5 months ago

Compugen and AstraZeneca agree to monetize rilvegostomig future royalties

AZN

Dec 17, 2025, 7:00 AM EST - 5 months ago

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Nov 11, 2025, 3:20 PM EST - 6 months ago

Compugen Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

Compugen Earnings Call Transcript: Q3 2025

2025-11-10T12:23:25.000Z - 6 months ago

Compugen reports Q3 EPS (7c), consensus (9c)

Nov 10, 2025, 7:00 AM EST - 6 months ago

Compugen Reports Third Quarter 2025 Results

Nov 4, 2025, 7:00 AM EST - 6 months ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 13, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 6, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present at SITC 2025

Sep 16, 2025, 11:30 AM EDT - 8 months ago

Compugen Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Compugen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:00 AM EDT - 9 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-07T11:35:33.000Z - 9 months ago

Compugen price target raised to $13 from $10 at Leerink

AZN

Aug 6, 2025, 8:30 AM EDT - 9 months ago

Compugen Earnings Call Transcript: Q2 2025

2025-08-06T11:26:38.000Z - 10 months ago

Compugen reports Q2 EPS (8c), consensus (9c)

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Compugen Reports Second Quarter 2025 Results

Jul 28, 2025, 7:00 AM EDT - 10 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 23, 2025, 7:00 AM EDT - 10 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

2025-07-21T11:05:54.000Z - 10 months ago

Compugen begins dosing in ovarian cancer trial

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jun 12, 2025, 7:00 AM EDT - 11 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

May 19, 2025, 8:30 AM EDT - 1 year ago

Compugen Earnings Call Transcript: Q1 2025

2025-05-19T11:05:25.000Z - 1 year ago

Options Volatility and Implied Earnings Moves Today, May 19, 2025

CBAT GILT GSL NIU QFIN RYAAY TCOM

May 19, 2025, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2025 Results

2025-05-13T11:12:07.000Z - 1 year ago

Compugen appoints Eran Ophir as CEO, announces leadership transitions

May 13, 2025, 7:00 AM EDT - 1 year ago

Compugen Announces Leadership Transitions Effective September 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Apr 9, 2025, 12:00 PM EDT - 1 year ago

Compugen Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 9:30 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q4 2024

2025-03-04T12:06:24.000Z - 1 year ago

Compugen reports Q4 EPS (7c) vs. 11c last year

Mar 4, 2025, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Compugen Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

2025-01-13T13:01:57.000Z - 1 year ago

Compugen initiated with an Outperform at Oppenheimer

AZN GILD

2025-01-08T12:25:57.000Z - 1 year ago

Compugen says first patient dosed in Phase 1 trial of COM503

Jan 8, 2025, 7:00 AM EST - 1 year ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

2024-11-27T12:06:19.000Z - 1 year ago

Compugen announces USPTO grants new patent for use of COM902

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 18, 2024, 8:35 AM EST - 1 year ago

Compugen Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q3 2024

2024-11-12T12:11:59.000Z - 1 year ago

Compugen reports Q3 EPS 1c, consensus 10c

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

2024-10-06T04:08:45.000Z - 1 year ago

Compugen management to meet with Oppenheimer

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Compugen Earnings Call Transcript: Q2 2024

2024-08-06T11:12:38.000Z - 1 year ago

Compugen reports Q2 EPS (2c), consensus (7c)

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

2024-07-29T11:02:52.000Z - 1 year ago

Compugen’s IND for COM503 in solid tumors cleared by FDA

GILD

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present at Upcoming Antibody Industrial Symposium

2024-05-30T11:11:27.000Z - 2 years ago

Compugen to receive $5M milestone payment from AstraZeneca

AZN

May 30, 2024, 7:00 AM EDT - 2 years ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings Call Transcript: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 2 years ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 2 years ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Compugen Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Compugen to Participate in Two Upcoming Investor Conferences

Estimize May. 13 at 10:00 AM

Wall St is expecting -0.07 EPS for $CGEN Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/cgen?chart=historical&metric_name=eps&utm_c

0 · Reply

TwitteringTom May. 12 at 1:59 PM

$CGEN whast this dumo

0 · Reply

KoalaFlipper May. 9 at 3:19 PM

$CGEN can we stay at 3,00$ per share?

0 · Reply

TwitteringTom May. 8 at 2:14 PM

$CGEN what we thinking? anything of note coming out on earnings?

0 · Reply

KoalaFlipper May. 8 at 10:03 AM

$CGEN Earnings Forecast: For the next quarter (reporting ~May 18, 2026), a small loss per share (-$0.07) is estimated, with revenue anticipated around $1.57M–$2.14M.

0 · Reply

Estimize May. 7 at 12:03 PM

Wall St is expecting -0.07 EPS for $CGEN Q1 [Reporting 05/18 BMO] http://www.estimize.com/intro/cgen?chart=historical&metric_name=eps&utm_c

0 · Reply

KoalaFlipper May. 4 at 9:30 PM

$CGEN buy the dips :)

0 · Reply

AGC_Trader May. 1 at 1:45 PM

$CGEN did anyone else see the spike to $3.17 in PM?

0 · Reply

KoalaFlipper May. 1 at 1:16 PM

$CGEN todays price prob gonna be 2,80+

0 · Reply

Sobo90 May. 1 at 9:04 AM

$CGEN didnt insiders just sell? Maybe nothing or they dont expect good news for some time.

1 · Reply

KoalaFlipper Apr. 30 at 5:56 PM

$CGEN only 218k traded share average is 300k to 400k shares.

0 · Reply

KoalaFlipper Apr. 30 at 5:54 PM

$CGEN buy that shit!!

0 · Reply

KoalaFlipper Apr. 30 at 5:50 PM

$CGEN looks like someone took the dip and its back at the good run hopefully.

0 · Reply

zerodayrounder Apr. 29 at 3:46 PM

$CGEN that was a nasty suck in but still seems like CGEN has lots of valuable stuff/partnerships/unigen platform etc. But definitely a dirty suck in in the short term.

0 · Reply

TwitteringTom Apr. 29 at 2:14 PM

$CGEN the party over?

1 · Reply

SuperGreenToday Apr. 29 at 1:13 PM

$CGEN Share Price: $2.73 Contract Selected: Dec 18, 2026 $2.5 Calls Buy Zone: $0.50 – $0.61 Target Zone: $0.91 – $1.11 Potential Upside: 73% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TwitteringTom Apr. 28 at 6:59 PM

$CGEN whats with the large DUMP

1 · Reply

Otus Apr. 28 at 6:25 PM

$CGEN I’d expect buyers to start coming in. I know I’m one of them.

1 · Reply

zerodayrounder Apr. 28 at 3:50 PM

$CGEN pretty nasty breakout rejection

0 · Reply

alexpitti Apr. 28 at 3:01 AM

meeting ceo of $CGEN tomorrow

2 · Reply

TwitteringTom Apr. 27 at 5:52 PM

$CGEN whats this trash

0 · Reply

KoalaFlipper Apr. 26 at 6:52 PM

$CGEN just remember friday there was traded 1.4M shares normally there only gets traded 322K share. so something is happening very soon..

1 · Reply

Market Cap	271.37M
Revenue (ttm)	72.76M
Net Income (ttm)	35.34M
EPS (ttm)	N/A
PE Ratio	7.84
Forward PE	N/A
Profit Margin	48.57%
Debt to Equity Ratio	0.00

Volume	323,900
Avg Vol	404,720
Day's Range	N/A - N/A
Shares Out	94.55M
Stochastic %K	65%
Beta	2.79
Analysts	Strong Sell
Price Target	$5.83